Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

Supplementary Figure S10 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer

<p>Genomic features of patients with long-term response (LTR) compared to non-LTR and progressive disease (PD).</p>

সংরক্ষণ করুন:

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক:	Rohit Thummalapalli (17314483) (author)
অন্যান্য লেখক:	Biagio Ricciuti (14951247) (author), Chaitanya Bandlamudi (15047205) (author), Daniel Muldoon (17314486) (author), Hira Rizvi (16547594) (author), Arielle Elkrief (15055750) (author), Jia Luo (15034764) (author), Joao V. Alessi (17314489) (author), Federica Pecci (15561470) (author), Giuseppe Lamberti (15024714) (author), Alessandro Di Federico (15561473) (author), Lingzhi Hong (17314492) (author), Jianjun Zhang (16041833) (author), John V. Heymach (14934698) (author), Don L. Gibbons (15055721) (author), Andrew J. Plodkowski (15028415) (author), Vignesh Ravichandran (15052350) (author), Mark T.A. Donoghue (15054209) (author), Chad Vanderbilt (15050973) (author), Marc Ladanyi (15050661) (author), Charles M. Rudin (11572933) (author), Mark G. Kris (15055774) (author), Gregory J. Riely (14961725) (author), Jamie E. Chaft (14937195) (author), Matthew D. Hellmann (14937198) (author), Natalie I. Vokes (17314495) (author), Mark M. Awad (14961722) (author), Adam J. Schoenfeld (15022025) (author)
প্রকাশিত:	2025
বিষয়গুলি:	Cancer Cancer Detection and Diagnosis Immuno-oncology Clinical Research and Trials Biomarkers Prognostic biomarkers Immunotherapy Biomarkers for immunotherapy Checkpoint blockade Lung Cancer Precision Medicine
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি

Supplementary Figure S1 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S11 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S12 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S13 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S14 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S15 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S2 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S5 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S6 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S7 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S8 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Figure S9 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Table S3 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Table S4 from Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer
অনুযায়ী: Rohit Thummalapalli (17314483)
প্রকাশিত: (2025)

Supplementary Tables S1-S10 from <i>ACTA2</i> Expression Predicts Survival and Is Associated with Response to Immune Checkpoint Inhibitors in Gastric Cancer
অনুযায়ী: Sunho Park (15053897)
প্রকাশিত: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
অনুযায়ী: Hansol Lee (15054787)
প্রকাশিত: (2025)

Table S2 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
অনুযায়ী: Joseph Toker (15399882)
প্রকাশিত: (2025)

Table S3 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
অনুযায়ী: Joseph Toker (15399882)
প্রকাশিত: (2025)

Table S4 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
অনুযায়ী: Joseph Toker (15399882)
প্রকাশিত: (2025)

Table S5 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
অনুযায়ী: Joseph Toker (15399882)
প্রকাশিত: (2025)

Table S6 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
অনুযায়ী: Joseph Toker (15399882)
প্রকাশিত: (2025)

Table S7 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
অনুযায়ী: Joseph Toker (15399882)
প্রকাশিত: (2025)

Table S8 from Clinical Importance of the lncRNA <i>NEAT1</i> in Cancer Patients Treated with Immune Checkpoint Inhibitors
অনুযায়ী: Joseph Toker (15399882)
প্রকাশিত: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
অনুযায়ী: Ankita Mitra (17141783)
প্রকাশিত: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
অনুযায়ী: Ankita Mitra (17141783)
প্রকাশিত: (2025)

Supplementary Table S1 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
অনুযায়ী: Aleksandar Obradovic (7549517)
প্রকাশিত: (2025)

Supplementary Table S2 from Immunostimulatory Cancer-Associated Fibroblast Subpopulations Can Predict Immunotherapy Response in Head and Neck Cancer
অনুযায়ী: Aleksandar Obradovic (7549517)
প্রকাশিত: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
অনুযায়ী: Ankita Mitra (17141783)
প্রকাশিত: (2025)

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
অনুযায়ী: Sonia A. Patel (15055688)
প্রকাশিত: (2025)

Supplementary Figure S2 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
অনুযায়ী: Sonia A. Patel (15055688)
প্রকাশিত: (2025)

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
অনুযায়ী: Sonia A. Patel (15055688)
প্রকাশিত: (2025)

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
অনুযায়ী: Sonia A. Patel (15055688)
প্রকাশিত: (2025)

Supplementary Figure S5 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC
অনুযায়ী: Sonia A. Patel (15055688)
প্রকাশিত: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
অনুযায়ী: Nigel Bundred (15046233)
প্রকাশিত: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
অনুযায়ী: Nigel Bundred (15046233)
প্রকাশিত: (2025)

Cannot write session to /tmp/vufind_sessions/sess_8kr7vbcq4j2l7fila0na6u3oue